Clinical Trial Update: Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of ATIR101 (T-lymphocyte enriched, host alloreactive T-cell depleted) in hematologic malignancy patients after haploidentical…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ATIR101 (ATIR101)

Snippet

Sponsor: Kiadis Pharma | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-12